Skip to content
DataLookout
Menu

NCT07465224

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 4 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Study completion pushed from May 28, 2027 to Jul 30, 2027
    • Site details revised
  2. Notable Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 1 of 5 entries
  3. Notable Enrollment reduced: 40 → 24 participants
    • Eligibility criteria expanded, about 10 words
    v5
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline in M-value
Timeframe: Baseline up to Month 3

Secondary (5)

Frequency of Adverse Events (AEs)
Change from Baseline in M/I
Change from Baseline in M-value
Change from Baseline in Endogenous Glucose Production (EGP)
Change from Baseline in Hemoglobin A1c (HbA1c)

Arms and interventions

ALN-4324Experimental

Participants will be administered a single dose of ALN-4324.

PlaceboPlacebo comparator

Participants will be administered a single dose of placebo.

Drugs: ALN-4324, Placebo

Sites

1 site in 1 country

  • Clinical Trial SiteChula Vista, California, United States